What is the recommended work‑up and treatment for anti‑protocadherin‑7 antibody‑associated membranous nephropathy?

Recommended Work-up and Treatment for Anti-Protocadherin-7 Antibody-Associated Membranous Nephropathy

For PCDH7-associated membranous nephropathy, treat according to standard KDIGO 2021 guidelines for primary membranous nephropathy based on risk stratification, using rituximab or cyclophosphamide with glucocorticoids for high-risk patients, while recognizing this is a rare, complement-poor subtype that may behave differently from PLA2R-associated disease.

Work-up and Diagnosis

Antigen Detection

• PCDH7-associated MN is diagnosed through immunohistochemistry showing bright granular staining along the glomerular basement membrane 1
• This represents approximately 5.7% of PLA2R-negative MN cases 1
• Mass spectrometry can detect PCDH7 in glomeruli with spectral counts ranging 6-24 1
• All PCDH7-positive cases must be negative for PLA2R, THSD7A, EXT1/EXT2, NELL1, and SEMA3B 1

Serologic Testing

• Western blot analysis can detect serum antibodies to nonreduced PCDH7 1
• Elution of IgG from frozen kidney tissue shows reactivity against PCDH7 1
• Unlike PLA2R-associated MN, the clinical utility of serum PCDH7 antibodies for monitoring disease activity is not yet established 2

Key Pathologic Features

• Minimal complement deposition is characteristic—seen in 12 of 14 PCDH7-associated cases 1
• Confocal microscopy demonstrates colocalization of PCDH7 and IgG along the glomerular basement membrane 1
• This complement-poor pattern distinguishes PCDH7-MN from PLA2R-associated disease

Associated Conditions to Screen For

• Look for underlying autoimmune disease, malignancy, medications, and infections 2
• The clinical associations specific to PCDH7 are still being defined, unlike NELL1 (malignancy association) or EXT1/2 (systemic autoimmunity) 3, 2

Treatment Approach

Risk Stratification (KDIGO 2021 Framework)

Apply standard KDIGO 2021 risk assessment 4:

Do NOT treat if:

• Proteinuria <3.5 g/day
• Serum albumin >30 g/L
• eGFR >60 mL/min/1.73 m²
• No progressive kidney function decline

Initiate immunosuppression for:

• Persistent nephrotic syndrome despite 6 months of conservative management
• Declining kidney function
• At least one risk factor for disease progression

First-Line Immunosuppressive Therapy

For medium-risk patients:

• Rituximab is preferred (375 mg/m² weekly × 4 doses or 1000 mg on days 1 and 15) 4
• Alternative: Rituximab combined with calcineurin inhibitors 5
• Alternative: Tacrolimus-based therapy for 6 months 4

For high-risk patients (rapid kidney function decline):

• Cyclophosphamide with alternate-month glucocorticoids for 6 months 4
• This provides more aggressive immunosuppression for patients at very high risk of kidney failure

Treatments to AVOID

• Do not use glucocorticoid monotherapy 5
• Do not use mycophenolate mofetil as initial treatment 5

Important Caveats for PCDH7-Associated MN

Complement-Poor Disease Pattern

The minimal complement deposition in PCDH7-MN 1 suggests potential differences in pathomechanism compared to complement-rich PLA2R-associated disease. However:

• No evidence yet supports modifying standard treatment protocols based on antigen type
• The complement-independent podocyte injury mechanisms demonstrated in THSD7A-MN 6 may also apply to PCDH7-MN
• Standard immunosuppression remains appropriate until specific data emerge

Monitoring Limitations

• Cannot use serum PCDH7 antibody levels for treatment monitoring like PLA2R antibodies 2
• Rely on traditional markers: proteinuria, serum albumin, and kidney function 5
• Monitor labs frequently when using ACE inhibitors/ARBs 4

Dual-Antigen Possibility

• PCDH7 can coexist with other antigens (PCDH7+PLA2R1, PCDH7+CNTN1 reported) 7
• Consider this if disease behaves atypically or responds poorly to treatment
• Dual-antigen MN may be underdiagnosed at 2.6% of PLA2R-negative cases 7

Supportive Care (Apply to All Cases)

Proteinuria and Blood Pressure Management

• Uptitrate ACE inhibitor or ARB to maximally tolerated dose 4
• Target systolic blood pressure <120 mmHg 4
• Target proteinuria <1 g/day (disease-dependent) 4
• Do not stop ACE inhibitor/ARB for modest creatinine increases up to 30% 4
• Use potassium-wasting diuretics to manage hyperkalemia and allow continued RAS blockade 4

Dietary and Lifestyle Modifications

• Restrict dietary sodium to <2.0 g/day 4
• Normalize weight, stop smoking, exercise regularly 4

Infection Prevention

• Critical priority when using immunosuppression 5
• Prophylaxis against Pneumocystis jirovecii when using cyclophosphamide or high-dose glucocorticoids
• Monitor for opportunistic infections with rituximab

Hyperlipidemia Management

• Consider statin therapy, particularly with other cardiovascular risk factors 4

Treatment of Resistant Disease or Relapse

For resistant disease:

• Use stepwise approach: switch from rituximab to cyclophosphamide-based regimen or vice versa 5
• Consider combination therapy (rituximab + calcineurin inhibitor) 5

For relapses:

• Adjust treatment based on individual risk profile 5
• Repeat the initially successful regimen if well-tolerated
• Consider maintenance therapy with calcineurin inhibitors

Post-Transplant Considerations

• PCDH7-MN can recur after kidney transplantation 5
• Monitor for proteinuria and perform protocol biopsies if indicated
• Treat recurrent disease similarly to native kidney disease